We have collected information about Intranasal Delivery Monoclonal Antibodies for you. Follow the links to find out details on Intranasal Delivery Monoclonal Antibodies.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC100244/
A number of monoclonal antibodies against the F glycoprotein are protective when delivered intranasally. In a study with cotton rats, eight different monoclonal antibodies against the F glycoprotein were delivered intranasally prior to virus challenge . Most protected against challenge when used at doses as low as 0.1 mg/kg.Author: Richard Weltzin, Thomas P. Monath
https://cvi.asm.org/content/17/9/1363
Sep 01, 2010 · Highly pathogenic avian H5N1 influenza viruses are endemic in poultry in Asia and pose a pandemic threat to humans. Since the deployment of vaccines against a pandemic strain may take several months, adequate antiviral alternatives are needed to minimize the effects and the spread of the disease. Passive immunotherapy is regarded as a viable alternative. Here, we show the development …Author: Jianqiang Ye, Hongxia Shao, Hongxia Shao, Danielle Hickman, Matthew Angel, Kemin Xu, Yibin Cai, Haic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944460/
Intranasal Delivery of an IgA Monoclonal Antibody Effective against Sublethal H5N1 Influenza Virus Infection in Mice † Jianqiang Ye , 1 Hongxia Shao , 1, 2 Danielle Hickman , 1 Matthew Angel , 1 Kemin Xu , 1 Yibin Cai , 1 Haichen Song , 3 Ron A. M. Fouchier , 4 Aijian Qin , 2 and Daniel R. Perez 1, *Author: Jianqiang Ye, Hongxia Shao, Hongxia Shao, Danielle Hickman, Matthew Angel, Kemin Xu, Yibin Cai, Haic...
https://www.bioworld.com/COVID19products
Human monoclonal antibodies developed using its VelociSuite technologies for treatment of COVID-19; in February 2020, development of a vaccine was planned; in March, it isolated hundreds o virus-neutralizing, fully human antibodies from humans who have recovered rom COVID-19, and plans to select the top two antibodies for a cocktail treatment ...
https://cvi.asm.org/content/cdli/17/9/1363.full.pdf
tion strategy. Intranasal administration of antibodies would allow the antibodies to directly reach their target in the respi-ratory track, which is the major site for influenza virus repli-cation in humans and other mammals (29, 33). IgA-mediated neutralization monoclonal antibody therapy against H5N1 hasAuthor: Jianqiang Ye, Hongxia Shao, Hongxia Shao, Danielle Hickman, Matthew Angel, Kemin Xu, Yibin Cai, Haic...
https://cmr.asm.org/content/12/3/383
Jul 01, 1999 · A number of monoclonal antibodies against the F glycoprotein are protective when delivered intranasally. In a study with cotton rats, eight different monoclonal antibodies against the F glycoprotein were delivered intranasally prior to virus challenge . Most protected against challenge when used at doses as low as 0.1 mg/kg.Author: Richard Weltzin, Thomas P. Monath
Searching for Intranasal Delivery Monoclonal Antibodies?
You can just click the links above. The data is collected for you.
